AstraZeneca Reports Data from the P-III (CAPItello-290) Study of Truqap Combined with Chemotherapy to Treat Triple-Negative Breast Cancer
Shots:
- The P-III (CAPItello-290) study aims to determine the safety & efficacy of Truqap + paclitaxel vs PBO + paclitaxel as a 1L treatment of locally advanced (inoperable) or metastatic TNBC
- The study did not reach its dual 1EP of OS in both the overall population and in patients having tumors associated with certain biomarker alterations (PIK3CA, AKT1 or PTEN). The safety profile aligned with that of each drug without any new safety concerns
- AstraZeneca is currently developing Truqap under the P-III (CAPItello-292) study for breast cancer and P-III (CAPItello-280 & CAPItello-281) in combinations for prostate cancer
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Truqap Plus Faslodex Receives the CHMP’s Positive Opinion for Treating Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
